524 related articles for article (PubMed ID: 34399317)
1. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
2. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
3. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
4. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
[TBL] [Abstract][Full Text] [Related]
5. Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey.
Caseby SCL; Woodhouse FA; Montgomery SM; Kroes MA; Duddy ME
Health Sci Rep; 2022 Jan; 5(1):e474. PubMed ID: 35229042
[TBL] [Abstract][Full Text] [Related]
6. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
7. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
8. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
9. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
10. The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe.
Nicholas R; Rodgers J; Witts J; Lerede A; Friede T; Hillert J; Forsberg L; Glaser A; Manouchehrinia A; Ramanujam R; Spelman T; Klyve P; Drahota J; Horakova D; Joensen H; Pontieri L; Magyari M; Ellenberger D; Stahmann A; Butzkueven H; Van Der Walt A; Bezlyak V; Lines C; Middleton R
Ther Adv Neurol Disord; 2023; 16():17562864231198963. PubMed ID: 37771841
[TBL] [Abstract][Full Text] [Related]
11. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
[TBL] [Abstract][Full Text] [Related]
12. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
O'Loughlin E; Hourihan S; Chataway J; Playford ED; Riazi A
Disabil Rehabil; 2017 Sep; 39(18):1821-1828. PubMed ID: 27685028
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
15. Diagnosing 'transition' to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians.
Hamdy E; Talaat F; Ramadan I; Marouf H; Hamdy MM; Sadallah H; El-Ashmawy GAH; Elsalamawy D; Said SM
Mult Scler Relat Disord; 2022 Apr; 60():103718. PubMed ID: 35279626
[TBL] [Abstract][Full Text] [Related]
16. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
17. Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Forsberg L; Spelman T; Klyve P; Manouchehrinia A; Ramanujam R; Mouresan E; Drahota J; Horakova D; Joensen H; Pontieri L; Magyari M; Ellenberger D; Stahmann A; Rodgers J; Witts J; Middleton R; Nicholas R; Bezlyak V; Adlard N; Hach T; Lines C; Vukusic S; Soilu-Hänninen M; van der Walt A; Butzkueven H; Iaffaldano P; Trojano M; Glaser A; Hillert J;
Mult Scler J Exp Transl Clin; 2023; 9(1):20552173231153557. PubMed ID: 36816812
[TBL] [Abstract][Full Text] [Related]
18. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E
Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696
[TBL] [Abstract][Full Text] [Related]
20. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
